Refine by
Drug Response Articles & Analysis
36 news found
Yang, L., et al (2024) introduces LungVis 1.0, an AI-driven imaging platform integrating light sheet fluorescence microscopy (LSFM) and deep learning for mapping nanoparticle (NP) deposition across murine lungs. The research highlights the advantages of aerosol-based delivery methods over traditional liquid-based approaches, emphasizing the uniformity of NP deposition in distal alveolar ...
“But in many instances, the Cellworks Platform has the ability to predict the human clinical response to drug candidates years earlier than traditional development pipelines. By predicting human clinical response much earlier in the drug development cycle, we can help pharmaceutical companies shave years off ...
“This study demonstrates the power of using Cellworks personalized therapy biosimulation to gain insight into individual patient mutanome, drug resistance pathways and novel biomarkers that determine their drug response and resistance to better inform treatment decisions for MDS ...
The first phase of the contract, which provides approximately $6 million to complete activities through the initial phase 1 study, coincides with grant support from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health. The new award builds on an existing partnership between Enalare Therapeutics and the BARDA DRIVe ReDIRECT (Repurposing ...
Immediate applications of Lifespin’s commercial services, which leverages access to Lifespin’s proprietary software and database, include quality control for synthetic/natural compounds, quantitative profiling of metabolites in liquid samples, monitoring of drug responses and organ-specific metabolic phenotyping, and precision nutrition to therapeutic ...
About PARIS® Test The PARIS® Test is a next generation diagnostic test that predicts drug responses by screening a broad panel of cancer drugs in patient-derived live tumor models by utilizing robotics, proprietary algorithms, and computational tools. ...
“The power of SEngine’s PARIS® platform to improve patient outcomes by providing oncologists individual drug effectiveness rankings as well as the innovation of new drugs will continue to propel SEngine ...
“This study confirmed that there are many dysregulated signaling pathways responsible for hallmark behaviors of cancer and variable drug response in gastroesophageal adenocarcinoma patients,” said Dr. ...
ET Title: Armoring T-cells with regulatable, membrane tethered cytokines using improved drug-responsive domain technology (cytoDRiVE®) Presenter: Dr. Dhruv K. ...
Obsidian Therapeutics, Inc., a biotechnology company pioneering engineered cell and gene therapies, today announced it will present data highlighting the potential of the company’s cytoDRiVE® platform technology, which allows regulation of protein expression using small molecule drugs. The data to be presented demonstrate tight control of membrane bound or shed IL12 (a ...
Beckman Coulter, a global clinical diagnostics leader, announces it will introduce new antipsychotic drug tests to laboratories and clinicians to address an unmet clinical need for 69 million people with serious mental conditions worldwide. ...
Joint research of biomarkers on platform technology of GI Innovation, GI-SMART™, and SpAC9 Pipeline, AI-powered biomarker discovery platform of CellKey Prediction of drug response on next-generation immuno-oncology, personalized cancer treatment effects… increasing reliability and efficiency of treatment GI Innovation, an innovative new ...
“Under the current standard of care, clinicians have only limited visibility into patients’ changing IOP and their IOP responses to drug therapy. The SBIR grant for IOP-Connect integration offers a path to effective IOP monitoring and control so that we can begin to determine what other factors affect glaucoma progression and vision ...
Joint research of biomarkers on platform technology of GI Innovation, GI-SMARTTM and SpAC9 Pipeline, AI-powered biomarker discovery platform of CellKey Prediction of drug response on next generation immuno-oncology, personalized cancer treatment effects… increasing Reliability and efficiency of treatment GI Innovation, a new innovative ...
Biomarkers are indicators that can determine the occurrence, development, and prognosis of diseases, and play an important role in early diagnosis, disease prevention, drug target confirmation, and drug response. Biomarker detection can provide insight into the mechanism of action or resistance of new drugs in disease models. ...
Early results suggest that GeneCentric’s Antifolate Predictive Response Signature (AF-PRS), one of the signatures included in the recently announced strategic collaboration with Labcorp, identified a distinct population of patients who clearly benefit from treatment with pemetrexed/platinum doublet chemotherapy. ...
” About PARIS® Test The PARIS® Test is a next generation diagnostic test that predicts drug responses integrating knowledge of cancer genomics with drug sensitivity testing of patient-derived live cells combined with robotics and proprietary algorithms. ...
About the rT(I)ME Explorer Platform GeneCentric’s broad pipeline of novel predictive response signatures has been built over the past decade using its proprietary RNA-based Tumor and Immune Micro-Environment (rT(I)ME) Explorer bioinformatics platform. These RNA-based response signatures allow for improved patient selection for new and existing targeted and ...
AI is and will remain a useful tool for the computing risk factor, classification, drug analysis, and response to disease, but its correct use and application is critical for optimum benefits. ...
ByJADBio
Obsidian’s cytoTIL product is comprised of TILs engineered with mbIL15 that is regulatable using a drug responsive domain (DRD) designed via our cytoDRiVE® platform. ...